Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · IEX Real-Time Price · USD
56.41
+0.50 (0.89%)
At close: Jul 19, 2024, 4:00 PM
56.42
+0.01 (0.02%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Cytokinetics Employees
Cytokinetics had 423 employees as of December 31, 2023. The number of employees increased by 14 or 3.42% compared to the previous year.
Employees
423
Change (1Y)
14
Growth (1Y)
3.42%
Revenue / Employee
$8,870
Profits / Employee
-$1,254,369
Market Cap
6.47B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 423 | 14 | 3.42% |
Dec 31, 2022 | 409 | 156 | 61.66% |
Dec 31, 2021 | 253 | 69 | 37.50% |
Dec 31, 2020 | 184 | 28 | 17.95% |
Dec 31, 2019 | 156 | 26 | 20.00% |
Dec 31, 2018 | 130 | -7 | -5.11% |
Dec 31, 2017 | 137 | 10 | 7.87% |
Dec 31, 2016 | 127 | 27 | 27.00% |
Dec 31, 2015 | 100 | 8 | 8.70% |
Dec 31, 2014 | 92 | 7 | 8.24% |
Dec 31, 2013 | 85 | 15 | 21.43% |
Dec 31, 2012 | 70 | -9 | -11.39% |
Dec 31, 2011 | 79 | -26 | -24.76% |
Dec 31, 2010 | 105 | -6 | -5.41% |
Dec 31, 2009 | 111 | 1 | 0.91% |
Dec 31, 2008 | 110 | -51 | -31.68% |
Dec 31, 2007 | 161 | 13 | 8.78% |
Dec 31, 2006 | 148 | -2 | -1.33% |
Dec 31, 2005 | 150 | -20 | -11.76% |
Dec 31, 2004 | 170 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Grifols | 23,737 |
Elanco Animal Health | 9,800 |
HealthEquity | 3,150 |
Jazz Pharmaceuticals | 2,800 |
Tempus AI | 1,952 |
Repligen | 1,783 |
Exelixis | 1,310 |
Madrigal Pharmaceuticals | 376 |
CYTK News
- 18 days ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire
- 5 weeks ago - Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants - GlobeNewsWire
- 6 weeks ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Cytokinetics to Participate in June Investor Conferences - GlobeNewsWire
- 7 weeks ago - Cytokinetics Announces Closing of Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Cytokinetics Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Cytokinetics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline - GlobeNewsWire